Business
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary monthly hormone therapy in 2026Creates commercial opportunity in the estimated up to $4.5 billion compounded hormone therapy market, enabling women to access an evidence-based solutionFour on-market products will accelerate revenue generation and provide path to profitabilityDaré expects to start reco
About this update from Dare Bioscience, Inc.
[{"type":"image","alt":"Daré Bioscience, Inc.","displaySize":"","headline":null,"caption":"Daré Bioscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":226,"url":"https://media.zenfs.com/en/globenewswire.com/e6d6ede7b4fb465dc2ad08194cf35dbd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ch5vpzW1QsXLUt._W_BLpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6d6ede7b4fb465dc2ad08194cf35dbd","width":300,"height":226}},"lazy":false},{"type":"text","content":"In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary monthly hormone therapy in 2026","length":229,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Creates commercial opportunity in the estimated up to $4.5 billion compounded hormone therapy market, enabling women to access an evidence-based solution","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"Four on-market products will accelerate revenue generation and provide path to profitability","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"Daré expects to start recording revenue in the 4th quarter of this year","length":76,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":321,"olType":false},{"type":"text","content":"Conference call today at 4:30 p.m. ET to discuss the further expanded business strategy to commercialize multiple solutions in 2025 and 2026","length":140,"tagName":"p"},{"type":"text","content":"2025 and 2026 Milestones","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Sildenafil Cream, 3.6% an investigational topical formulation of sildenafil being developed to treat female sexual arousal disorder, targeting availability via prescription as a Section 503B compounded drug this year","length":216,"tagName":"p"}]},{"val":[{"type":"text","content":"DARE-HRT1 an investigational monthly intravaginal hormone therapy being developed to treat the vasomotor symptoms of menopause, targeting availability via prescription as a Section 503B compounded drug next year","length":211,"tagName":"p"}]},{"val":[{"type":"text","content":"Vaginal probiotics, designed to restore a healthy vaginal microbiome, targ...